Santacroce Antonio, Tuleasca Constantin, Liščák Roman, Motti Enrico, Lindquist Christer, Radatz Matthias, Gatterbauer Brigitte, Lippitz Bodo E, Martínez Álvarez Roberto, Martínez Moreno Nuria, Kamp Marcel A, Sandvei Skeie Bente, Schipmann Stephanie, Longhi Michele, Unger Frank, Sabin Ian, Mindermann Thomas, Bundschuh Otto, Horstmann Gerhard A, van Eck A T C J, Walier Maja, Berres Manfred, Nakamura Makoto, Steiger Hans Jakob, Hänggi Daniel, Fortmann Thomas, Zawy Alsofy Samer, Régis Jean, Ewelt Christian
Department of Neurosurgery, St. Barbara-Klinik Hamm-Heessen, 59073 Hamm, Germany.
Department of Medicine, Faculty of Health, Witten/Herdecke University, 58455 Witten, Germany.
Cancers (Basel). 2022 Aug 22;14(16):4047. doi: 10.3390/cancers14164047.
Cavernous sinus meningiomas (CSMs) remain a surgical challenge due to the intimate involvement of their contained nerves and blood vessels. Stereotactic radiosurgery (SRS) is a safe and effective minimally invasive alternative for the treatment of small- to medium-sized CSMs. Objective: To assess the medium- to long-term outcomes of SRS for CSMs with respect to tumour growth, prevention of further neurological deterioration and improvement of existing neurological deficits. This multicentric study included data from 15 European institutions. We performed a retrospective observational analysis of 1222 consecutive patients harbouring 1272 benign CSMs. All were treated with Gamma Knife stereotactic radiosurgery (SRS). Clinical and imaging data were retrieved from each centre and entered into a common database. All tumours with imaging follow-up of less than 24 months were excluded. Detailed results from 945 meningiomas (86%) were then analysed. Clinical neurological outcomes were available for 1042 patients (85%). Median imaging follow-up was 67 months (mean 73.4, range 24-233). Median tumour volume was 6.2 cc (+/-7), and the median marginal dose was 14 Gy (+/-3). The post-treatment tumour volume decreased in 549 (58.1%), remained stable in 336 (35.6%) and increased in only 60 lesions (6.3%), yielding a local tumour control rate of 93.7%. Only 27 (2.8%) of the 60 enlarging tumours required further treatment. Five- and ten-year actuarial progression-free survival (PFS) rates were 96.7% and 90.1%, respectively. Tumour control rates were higher for women than men ( = 0.0031), and also for solitary sporadic meningiomas ( = 0.0201). There was no statistically significant difference in outcome for imaging-defined meningiomas when compared with histologically proven WHO Grade-I meningiomas ( = 0.1212). Median clinical follow up was 61 months (mean 64, range 6-233). Permanent morbidity occurred in 5.9% of cases at last follow-up. Stereotactic radiosurgery is a safe and effective method for treating benign CSM in the medium term to long term.
海绵窦脑膜瘤(CSMs)由于其内部神经和血管的紧密受累,仍然是一个手术挑战。立体定向放射外科(SRS)是治疗中小型CSMs的一种安全有效的微创替代方法。目的:评估SRS治疗CSMs的中长期疗效,包括肿瘤生长、预防进一步神经功能恶化以及改善现有神经功能缺损。这项多中心研究纳入了来自15个欧洲机构的数据。我们对1222例连续患有1272个良性CSMs的患者进行了回顾性观察分析。所有患者均接受伽玛刀立体定向放射外科(SRS)治疗。从每个中心检索临床和影像数据并录入一个公共数据库。排除影像随访时间少于24个月的所有肿瘤。然后对945例脑膜瘤(86%)的详细结果进行分析。1042例患者(85%)有临床神经学结果。影像随访的中位时间为67个月(平均73.4个月,范围24 - 233个月)。肿瘤体积中位数为6.2立方厘米(±7),中位边缘剂量为14 Gy(±3)。治疗后肿瘤体积缩小的有549例(58.1%),保持稳定的有336例(35.6%),仅60个病灶增大(6.3%),局部肿瘤控制率为93.7%。60个增大的肿瘤中只有27个(2.8%)需要进一步治疗。5年和10年的无进展生存(PFS)精算率分别为96.7%和90.1%。女性的肿瘤控制率高于男性(P = 0.0031),孤立性散发性脑膜瘤的肿瘤控制率也更高(P = 0.0201)。与组织学证实的WHO I级脑膜瘤相比,影像诊断的脑膜瘤在疗效上无统计学显著差异(P = 0.1212)。临床随访的中位时间为61个月(平均64个月,范围6 - 233个月)。在最后一次随访时,5.9%的病例出现永久性并发症。立体定向放射外科是中长期治疗良性CSMs的一种安全有效的方法。